Doha- Sharikat Mubasher: Qatar Investment Authority (QIA) joined a $150 million Series B financing round for Latigo Biotherapeutics, a biotechnology company developing non-opioid pain treatments.
As per an official press release by the company, the funding will support Latigo’s clinical development of its selective Nav1.8 inhibitors, designed to provide effective pain relief without the risks associated with opioids.
The round was led by funds managed by Blue Owl Capital and included participation from Deep Track Capital, Access Biotechnology, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital. Existing investors such as Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments also took part.
Nima Farzan, Latigo CEO Nima Farzan said the funding will accelerate efforts to deliver innovative, non-addictive pain treatments. QIA’s participation reflects its growing investment footprint in global biotech innovation, supporting advancements that address critical healthcare needs.
